<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tg Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/tg-therapeutics-inc</link>
<description>Latest news and press releases for Tg Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tg-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c8e578dffbe2df11c0f8.webp</url>
<title>Tg Therapeutics Inc</title>
<link>https://6ix.com/company/tg-therapeutics-inc</link>
</image>
<item>
<title>TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-announces-data-presentations-for-briumvi-in-multiple-sclerosis-at-the-american-academy-of-neurology-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-announces-data-presentations-for-briumvi-in-multiple-sclerosis-at-the-american-academy-of-neurology-2026-annual-meeting</guid>
<pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
<description>NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI®</description>
</item>
<item>
<title>TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-announces-completion-of-enrollment-for-the-phase-3-trial-evaluating-subcutaneous-briumvi</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-announces-completion-of-enrollment-for-the-phase-3-trial-evaluating-subcutaneous-briumvi</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first</description>
</item>
<item>
<title>TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-secures-an-additional-dollar500-million-in-non-dilutive-capital-from-blue-owl-and-expands-share-repurchase-program-to-dollar300-million</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-secures-an-additional-dollar500-million-in-non-dilutive-capital-from-blue-owl-and-expands-share-repurchase-program-to-dollar300-million</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives NEW YORK, March</description>
</item>
<item>
<title>Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/data-published-in-neurology-and-therapy-demonstrate-significant-reductions-in-relapse-and-mri-activity-with-briumvir-in-people-with-highly-active-relapsing-multiple-sclerosis</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/data-published-in-neurology-and-therapy-demonstrate-significant-reductions-in-relapse-and-mri-activity-with-briumvir-in-people-with-highly-active-relapsing-multiple-sclerosis</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post hoc pooled analysis of</description>
</item>
<item>
<title>TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-announces-schedule-of-data-presentations-for-briumvir-ublituximab-in-multiple-sclerosis-at-the-american-academy-of-neurology-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-announces-schedule-of-data-presentations-for-briumvir-ublituximab-in-multiple-sclerosis-at-the-american-academy-of-neurology-2026-annual-meeting</guid>
<pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
<description>NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting</description>
</item>
<item>
<title>Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/precision-biosciences-receives-dollar75m-in-proceeds-from-tg-therapeutics-for-azer-cel-clinical-milestone-in-multiple-sclerosis-1</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/precision-biosciences-receives-dollar75m-in-proceeds-from-tg-therapeutics-for-azer-cel-clinical-milestone-in-multiple-sclerosis-1</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>– Milestone payments include $5.25 million cash and $2.25 million purchase of Precision stock– – Cash received supports Precision’s expected cash runway</description>
</item>
<item>
<title>TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-raises-briumvi-revenue-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-raises-briumvi-revenue-guidance</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million,</description>
</item>
<item>
<title>TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-to-host-conference-call-on-fourth-quarter-and-full-year-2025-financial-results-and-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-to-host-conference-call-on-fourth-quarter-and-full-year-2025-financial-results-and-business-update</guid>
<pubDate>Mon, 23 Feb 2026 12:30:00 GMT</pubDate>
<description>Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ETNEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter and full year 2025 and to provide a business outlook for 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-80</description>
</item>
<item>
<title>Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/long-term-data-published-jama-123000484</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/long-term-data-published-jama-123000484</guid>
<pubDate>Tue, 17 Feb 2026 12:30:00 GMT</pubDate>
<description>During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 5 years of continuous treatment, with no new safety signals emerging with prolonged treatment NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of long term/five-year data from the ongoing open-label extension (OLE) of the Pha</description>
</item>
<item>
<title>TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-announces-collaboration-christina-211700784</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-announces-collaboration-christina-211700784</guid>
<pubDate>Sun, 08 Feb 2026 21:17:00 GMT</pubDate>
<description>Campaign debuted during Super Bowl LX and introduced www.NextInMS.com, a new platform designed to create space for honest conversation among people living with MS A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced a collaboration with actress Christina Applegate to help raise awareness of multiple sclerosis (MS) and support meaningful conversations for those living</description>
</item>
<item>
<title>TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-announces-presentation-data-123000612</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-announces-presentation-data-123000612</guid>
<pubDate>Fri, 06 Feb 2026 12:30:00 GMT</pubDate>
<description>NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in San Diego, California. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, “We are pleased to share data at this year’s ACTRIMS a</description>
</item>
<item>
<title>TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-announces-schedule-data-123000335</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-announces-schedule-data-123000335</guid>
<pubDate>Tue, 27 Jan 2026 12:30:00 GMT</pubDate>
<description>NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 5 – 7, 2026 in San Diego, California. Abstracts are now available online and can be accessed on the ACTRIMS meeting website at www.forum.actrims.org. Details of the upcoming presentation</description>
</item>
<item>
<title>TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-provides-preliminary-fourth-212500865</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-provides-preliminary-fourth-212500865</guid>
<pubDate>Tue, 13 Jan 2026 21:25:00 GMT</pubDate>
<description>Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594 million, respectivelyFull Year 2026 target total global revenue of approximately $875-900 million, including BRIUMVI U.S. net product revenue of approximately $825-850 million NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics), today announc</description>
</item>
<item>
<title>TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-participate-44th-annual-123000484</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-participate-44th-annual-123000484</guid>
<pubDate>Wed, 07 Jan 2026 12:30:00 GMT</pubDate>
<description>Presentation scheduled for Tuesday, January 13, 2026, at 1:30 PM PSTNEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Tuesday, January 13, 2026, at 1:30 PM PST. A live webcast of this presentation will be available on the Events page, located within the Investors</description>
</item>
<item>
<title>TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-participate-8th-annual-evercore-healthcare-conference-2025-11-28</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-participate-8th-annual-evercore-healthcare-conference-2025-11-28</guid>
<pubDate>Fri, 28 Nov 2025 05:00:00 GMT</pubDate>
<description>Fireside chat scheduled for Tuesday, December 2, 2025 at 12:30 PM ET NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today</description>
</item>
<item>
<title>TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-makes-2025-deloitte-technology-fast-500tm-list-americas-fastest</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-makes-2025-deloitte-technology-fast-500tm-list-americas-fastest</guid>
<pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
<description>NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number 27 on the Deloitte Technology Fast 500™, a</description>
</item>
<item>
<title>TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-participate-td-cowen-immunology-inflammation-summit-2025-11-10</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-participate-td-cowen-immunology-inflammation-summit-2025-11-10</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Fireside chat scheduled for Wednesday November 12, 2025 at 10:00 AM ET NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today</description>
</item>
<item>
<title>TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-reports-third-quarter-2025-financial-results-and-raises-briumvi</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-reports-third-quarter-2025-financial-results-and-raises-briumvi</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million Raises full year 2025 global revenue target to $600</description>
</item>
<item>
<title>TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-host-conference-call-third-quarter-2025-financial-results-and</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-host-conference-call-third-quarter-2025-financial-results-and</guid>
<pubDate>Fri, 31 Oct 2025 04:00:00 GMT</pubDate>
<description>Conference Call to be Held Monday, November 3, 2025, at 8:30 am ET NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today</description>
</item>
<item>
<title>TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI</title>
<link>https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-completes-enrollment-phase-3-enhance-trial-evaluating-its-new</link>
<guid isPermaLink="true">https://6ix.com/company/tg-therapeutics-inc/news/tg-therapeutics-completes-enrollment-phase-3-enhance-trial-evaluating-its-new</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of</description>
</item>
</channel>
</rss>